Formulation Development

Antibody-dependent cellular phagocytosis (ADCP) is one crucial MOA of many antibody therapies. It is defined as a highly regulated process by which antibodies eliminate bound targets via connecting its Fc domain to specific receptors on phagocytic cells, and eliciting phagocytosis.

Preclinical in vivo ADME study is an important component of the drug development process which is designed to investigate the absorption, distribution, metabolism, and excretion of test articles. In addition to supporting drug discovery, lead candidate selection, preclinical testing, and clinical programs, in vivo ADME study also plays a key…

There are plenty of sophisticated mechanisms in the human immune system to identify and eliminate unwanted cells (e.g., viral infection and tumor). Amongst these, antibody-dependent cellular cytotoxicity, namely ADCC, plays a crucial role.

6-OHDA is a selective catecholaminergic neurotoxin that is used, mainly, to generate lesions in the nigrostriatal dopamine (DA) neurons in rats. This neurotoxin for PD model was first introduced in 1968 by Ungerstedt when he noticed that a unilateral application of 6-OHDA into the nucleus caudatus putamen or the substantia…

Parkinson's disease (PD) is a neurodegenerative disorder that affects about 1.5% of the global population over 65 years of age. Robust, well-validated pre-clinical models of PD are valuable tools for understanding the biology and possible treatment of this complex disease.